# Advances of oncolytic vaccinia viruses armed with interleukin in tumor therapy

## TL;DR

This paper explores how vaccinia viruses modified with interleukins can improve cancer treatment by boosting the immune response and combining with other therapies.

## Contribution

The paper introduces novel combinatorial strategies and solutions to immune clearance challenges in oncolytic vaccinia virus therapy.

## Key findings

- Armed vaccinia viruses enhance immune cell infiltration and suppress immunosuppressive elements in tumors.
- Combinatorial therapies with checkpoint inhibitors and metabolic modulators improve treatment outcomes.
- Strategies like polymer encapsulation and AI-driven designs are proposed to optimize virus delivery and efficacy.

## Abstract

Oncolytic vaccinia viruses armed with interleukins represent a promising frontier in tumor therapy. Oncolytic vaccinia viruses express IL-2, IL-10, IL-12, IL-15, IL-21, IL-23, IL-24, and IL-36γ remodel the tumor microenvironment,enhance immune cell infiltration, suppress immunosuppressive elements and promot systemic antitumor immunity. Combinatorial strategies with chemotherapy, radiotherapy, metabolic modulators, immune checkpoint inhibitors, or natural compounds amplify therapeutic efficacy for tumors. In addition, we review the existing solutions to the problems of the immune clearance of virus, such as the use of inhibitors to prevent neutralizing antibodies from binding to the virus and the use of polymer encapsulation or mesenchymal stem cell loading. We also discussed Current directions include optimizing delivery systems, leveraging Artificial Intelligence for personalized designs of Oncolytic vaccinia virus inserted interleukins to guide the research in the future.